--- title: Mounjaro Is Now Approved to Lower the Risk of Heart Events description: The new indication for Eli Lilly's drug is for people with Type 2 diabetes. canonical: https://time.com/article/2026/08/28/eli-lilly-drug-mounjaro-approved-to-lower-heart-events-risk/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2026-08-28T18:56:58.000Z article:modified_time: 2026-08-28T19:34:19.557Z article:section: Health og:title: Mounjaro Is Now Approved to Lower the Risk of Heart Events og:description: The new indication for Eli Lilly's drug is for people with Type 2 diabetes. og:url: https://time.com/article/2026/08/28/eli-lilly-drug-mounjaro-approved-to-lower-heart-events-risk/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltaa07989c9c1cfa80/6a91e2a74b1dc0516ad341da/pngwithsrgbspace.png?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 5792 og:image:height: 3258 og:image:alt: pngwithsrgbspace.png og:type: article twitter:card: summary_large_image twitter:title: Mounjaro Is Now Approved to Lower the Risk of Heart Events twitter:description: The new indication for Eli Lilly's drug is for people with Type 2 diabetes. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltaa07989c9c1cfa80/6a91e2a74b1dc0516ad341da/pngwithsrgbspace.png?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # Mounjaro Is Now Approved to Lower the Risk of Heart Events > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=cb6eda9a-bea0-40f5-a22a-6175965dc4c5&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Daily | | Worth Your Time | A weekly guide to what to watch, read, and more | Tuesday and Saturday (2x per week) | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Monday to Saturday (3x per week) | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=cb6eda9a-bea0-40f5-a22a-6175965dc4c5&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=cb6eda9a-bea0-40f5-a22a-6175965dc4c5&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (daily health), Worth Your Time (culture, twice weekly), D.C. Brief (Washington politics, three times a week), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Aug 28, 2026 6:56 PM UTC  Eli Lilly Co.  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Aug 28, 2026 6:56 PM UTC While the popular [GLP-1 medications](https://time.com/7382492/weight-loss-drugs-prevent-treat-addiction-study/) continue to help people [control diabetes and weight](https://time.com/article/2026/03/18/lilly-diabetes-weight-loss-drug-retatrutide/), the versatile drugs are also starting to address [other health conditions](https://time.com/7207986/health-risks-benefits-weight-loss-drugs-ozempic-wegovy/) as well. On Aug. 28, the U.S. Food and Drug Administration (FDA) [approved](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular) Mounjaro to lower the risk of heart events, including heart attack, in people with diabetes. Made by Eli Lilly and Company, Mounjaro is already approved to [help manage blood sugar.](https://time.com/6284941/mounjaro-weight-loss/) Mounjaro affects two of the hormones in the incretin class—GLP-1 and GIP—that have become powerful targets for controlling blood sugar and weight. In the study Lilly submitted to the FDA, researchers compared heart events among people with Type 2 diabetes who either took Mounjaro or another Lilly drug for diabetes, called Trulicity, which targets only GLP-1\. People taking Mounjaro had an 8% lower rate of heart attack, stroke, or heart-related death compared to those taking Trulicity. In previous studies, Trulicity helped people with and without a history of heart conditions to lower their risk of having a heart event [by 12%](https://trulicity.lilly.com/hcp/efficacy-weight/cardiovascular-disease) compared to those receiving placebo. “This study was in patients with Type 2 diabetes, in whom the No. 1 cause of death is cardiovascular disease,” says Dr. Rachel Batterham, senior vice president of medical innovation and external engagement for cardiometabolic health at Lilly. “So reducing that risk is critically important.” Batterham says Lilly decided to compare Mounjaro’s potential in reducing heart risk to an existing drug, Trulicity, that already reduced heart risk to see if Mounjaro would have any additional benefit. “We set ourselves a very high bar,” she says. But the study design means that the heart benefit results cannot be directly compared to Mounjaro’s competitor drug, Ozempic, from Novo Nordisk. Ozempic, which is approved to treat diabetes, and Novo Nordisk’s [Wegovy](https://time.com/7343023/wegovy-pill-weight-loss-drugs-novo-nordisk/), approved to treat overweight and obesity, are both approved to lower the risk of heart disease risk by 20%. Lilly is, however, currently conducting a study tracking people who don’t have Type 2 diabetes who take the weight-loss version of their drug, [Zepbound](https://time.com/6333255/fda-approval-zepbound-tirzepatide-mounjaro-weight-loss/), for heart events. In that study, says Batterham, the researchers will be looking at whether Zepbound can prevent second heart events from occurring in people who have already had one, as well as whether the drug can prevent first heart events from occurring. For now, she says, the new indication means that for people with Type 2 diabetes already taking Mounjaro, doctors can discuss the fact that in addition to controlling their blood sugar, the drug may also help them to lower their risk of having heart events. And for those who don’t have diabetes and are taking Zepbound for weight loss only, “what we could say is that we know people with Type 2 diabetes see this \[heart\] benefit, but as yet we don’t have the data to say that this same benefit applies in people without diabetes—but we will have those data next year.” ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/article/2026/08/28/eli-lilly-drug-mounjaro-approved-to-lower-heart-events-risk/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/article/2026/08/28/eli-lilly-drug-mounjaro-approved-to-lower-heart-events-risk/"},"headline":"Mounjaro Is Now Approved to Lower the Risk of Heart Events","datePublished":"2026-08-28T18:56:58.000Z","dateModified":"2026-08-28T19:34:19.557Z","description":"The new indication for Eli Lilly's drug is for people with Type 2 diabetes.","url":"https://time.com/article/2026/08/28/eli-lilly-drug-mounjaro-approved-to-lower-heart-events-risk/","keywords":["Heart Disease","Weight loss"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltaa07989c9c1cfa80/6a91e2a74b1dc0516ad341da/pngwithsrgbspace.png?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltaa07989c9c1cfa80/6a91e2a74b1dc0516ad341da/pngwithsrgbspace.png?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"pngwithsrgbspace.png","caption":"","creditText":"Eli Lilly Co.","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/heart-disease/","name":"Heart Disease"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/article/2026/08/28/eli-lilly-drug-mounjaro-approved-to-lower-heart-events-risk/","name":"Mounjaro Is Now Approved to Lower the Risk of Heart Events"}}]}] ```